

WY-DUR
Wyoming Drug Utilization Review Board
Dept. 3375
1000 E. University Avenue
Laramie, WY 82071
307-766-6750

Aimee Lewis, Pharm.D., M.B.A.
DUR Manager
Kurt Hopfensperger, M.D., J.D.
Chair
Rebecca Ormas, R.Ph.
Vice Chair

November 21, 2011

Dear Prescriber:

The Wyoming Pharmacy and Therapeutics Committee is charged with development of prior authorization criteria to address the utilization of medications in the Wyoming Medicaid program. As a part of this process, the Committee is asking you to participate in an effort to enlist the expertise of practitioners affected by the following criteria recently drafted by the Committee.

**Prior authorization criteria
November 17, 2011**

Arcapta will be approved for patients over the age of 40 with a COPD diagnosis.

Approval of Gralise will require a 60-day trial and documented response to immediate release gabapentin with a credible reason for need of the once daily formulation. The dose will be limited to 1800 mg per day.

Approval of Cialis will require a 90-day trial and failure of all other medications for BPH.

Elidel and Protopic will be approved following a 21-day trial and failure of both a medium and high potency preferred topical corticosteroid.

Letairis and Tracleer will require a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.

Please provide comments on the listed criteria by December 31, 2011 to my attention at the University of Wyoming School of Pharmacy address provided above. Your participation and guidance to the WY-P&T Committee are invaluable and I would like to thank you for taking the time to review the information.

Sincerely,

Aimee Lewis

Aimee Lewis, Pharm.D., M.B.A.
WY-DUR Program Manager